Ovarian Cancer Clinical Trial
Official title:
A Standardized Nursing Intervention Protocol for Ovarian Cancer as a Chronic Illness
RATIONALE: A teaching intervention with an advanced practice nurse may help reduce
psychosocial and symptom distress and improve the well-being and quality of life of patients
with ovarian cancer.
PURPOSE: This clinical trial is studying the effects of a teaching intervention with an
advanced practice nurse on quality of life and psychosocial and symptom distress in patients
with ovarian cancer.
OBJECTIVES:
- To compare the effects of a standardized nursing intervention protocol (SNIP) model
with an advanced practice nurse vs usual care on overall quality of life and
psychological distress from initial treatment to 6 months after diagnosis in patients
with ovarian cancer.
- To compare symptom control in these patients.
- To compare geriatric assessment outcomes in these patients.
- To compare the effects of the SNIP intervention vs usual care on resource use by these
patients.
- To test the effects of SNIP on patients' and clinicians' satisfaction with care.
- To describe the effects of SNIP on management of transitions from one phase of chronic
illness to another.
- To identify subgroups of patients with ovarian cancer who benefit most from the SNIP in
relation to sociodemographic characteristics, disease/treatment factors, and geriatric
assessment predictors.
- To obtain feedback from clinicians regarding interpretation of findings and application
to the routine care of ovarian cancer patients.
OUTLINE: Patients are stratified according to age (18 to 60 years vs 61 years and over).
Patients are sequentially enrolled into 1 of 2 groups. Patients are initially enrolled in
group I. Once enrollment in group I is completed, additional patients are enrolled in group
II.
- Group I (usual care): Patients complete questionnaires, including the FACT-Ovarian,
Memorial Symptom Assessment Scale, Psychological Distress Thermometer, and
Comprehensive Geriatric Assessment, at baseline and at 3 and 6 months. Clinicians also
complete questionnaires, including the Clinician Satisfaction with Intervention
Questionnaire. Patients' medical charts are reviewed to collect information about
treatment, episodes of care, and readmissions.
- Group II (advanced practice nurse [APN] intervention): Patients undergo face-to-face
individualized teaching sessions with an APN twice a month for 2 months. The sessions
focus on the patient's physical, psychological, social, and spiritual well-being and
the content is tailored to the patient's preferences and needs. Patients are then
contacted by the APN via telephone once a month for 4 months to clarify questions and
content from the teaching sessions, review any patient concerns, including concerns
associated with a transition, and coordinate interdisciplinary resources, including
community resources, as needed. Patients and clinicians complete questionnaires as in
group I. Patients' medical charts are also reviewed.
;
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
| Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
| Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
| Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
| Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
| Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |